Clinigen (LON:CLIN) said it will oversee the managed access programme for Takeda Pharmaceutical’s ixazomib that treats the blood cancer multiple myeloma.
The firm’s managed access programmes bring drugs and treatments to markets where they don’t have full regulatory sign off.
For instance, while ixazomib has the green light in the US, it is still in the process of being signed off by regulators here in Europe.
So Clinigen will make it possible for patients outside the America with the disease to receive the new treatment.
"Multiple myeloma is a devastating blood cancer with thousands of patients requiring treatment all over the world,” said Simon Estcourt, the head of Clinigen’s managed access business.
“As leaders in the specialist management of ethical access to innovative medicines, we will use our regulatory capabilities and global reach to support Takeda to provide early access for ixazomib - helping physicians to treat their patients with a current unmet medical need."